H. Dijstelbloem, R. Scheepers, W. Oost, C. Stegeman, W. Van-der-pol et al., Fc? receptor polymorphisms in Wegener's granulomatosis: risk factors for disease relapse, 9<1823::AID-ANR5>3.0.CO, pp.1823-1830, 1999.

H. Dijstelbloem, M. Bijl, R. Fijnheer, R. Scheepers, W. Oost et al., Fc?? receptor polymorphisms in systemic lupus erythematosus: Association with disease and in vivo clearance of immune complexes, 12<2793: :AID-ANR20>3.0.CO, pp.2793-800, 2000.
DOI : 10.1002/1529-0131(200012)43:12<2793::AID-ANR20>3.0.CO;2-6

P. Bruhns, Properties of mouse and human IgG receptors and their contribution to disease models, Blood, vol.119, issue.24, pp.5640-5649, 2012.
DOI : 10.1182/blood-2012-01-380121

G. Cartron, L. Dacheux, G. Salles, P. Solal-celigny, P. Bardos et al., Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor Fcgamma RIIIa gene, Blood, vol.99, issue.3, pp.754-762, 2002.
DOI : 10.1182/blood.V99.3.754

N. Cooper, R. Stasi, S. Cunningham-rundles, E. Cesarman, J. Mcfarland et al., Platelet-associated antibodies, cellular immunity and FCGR3a genotype influence the response to rituximab in immune thrombocytopenia, British Journal of Haematology, vol.112, issue.4, pp.539-586, 2012.
DOI : 10.1111/j.1365-2141.2012.09184.x

A. Ruyssen-witrand, S. Rouanet, B. Combe, M. Dougados, L. Loët et al., Fc?? receptor type IIIA polymorphism influences treatment outcomes in patients with rheumatoid arthritis treated with rituximab, Annals of the Rheumatic Diseases, vol.71, issue.6, pp.875-882, 2012.
DOI : 10.1136/annrheumdis-2011-200337

E. Louis, E. Ghoul, Z. Vermeire, S. Dall-'ozzo, S. Rutgeerts et al., Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease, Alimentary Pharmacology and Therapeutics, vol.1, issue.5, pp.511-520, 2004.
DOI : 10.1002/1529-0131(199901)42:1<90::AID-ANR12>3.0.CO;2-A

R. Moroi, K. Endo, Y. Kinouchi, H. Shiga, Y. Kakuta et al., FCGR3A-158 polymorphism influences the biological response to infliximab in Crohn???s disease through affecting the ADCC activity, Immunogenetics, vol.113, issue.4, pp.265-71, 2013.
DOI : 10.1007/s00251-013-0679-8

Z. Tutuncu, A. Kavanaugh, N. Zvaifler, M. Corr, R. Deutsch et al., Fc?? receptor type IIIA polymorphisms influence treatment outcomes in patients with inflammatory arthritis treated with tumor necrosis factor ??-blocking agents, Arthritis & Rheumatism, vol.64, issue.9, pp.2693-2699, 2005.
DOI : 10.1002/art.21266

A. Kastbom, J. Bratt, S. Ernestam, J. Lampa, L. Padyukov et al., Fc?? receptor type IIIA genotype and response to tumor necrosis factor ?????blocking agents in patients with rheumatoid arthritis, Arthritis & Rheumatism, vol.43, issue.2, pp.448-52, 2007.
DOI : 10.1002/art.22390

T. Fujimoto, M. Inoue, T. Shimomura, and K. Fujimura, Involvement of Fc? receptor polymorphism in the therapeutic response of idiopathic thrombocytopenic purpura, Br J Haematol, vol.115, 2001.

S. Shrestha, H. Wiener, A. Shendre, R. Kaslow, J. Wu et al., Role of Activating Fc??R Gene Polymorphisms in Kawasaki Disease Susceptibility and Intravenous Immunoglobulin Response, Circulation: Cardiovascular Genetics, vol.5, issue.3, pp.309-325, 2012.
DOI : 10.1161/CIRCGENETICS.111.962464

R. Makowsky, H. Wiener, T. Ptacek, M. Silva, A. Shendre et al., Fc??R gene copy number in Kawasaki disease and intravenous immunoglobulin treatment response, Pharmacogenetics and Genomics, vol.23, issue.9, pp.455-62, 2013.
DOI : 10.1097/FPC.0b013e328363686e

S. Shrestha, H. Wiener, A. Olson, J. Edberg, N. Bowles et al., Functional FCGR2B gene variants influence intravenous immunoglobulin response in patients with Kawasaki disease, Journal of Allergy and Clinical Immunology, vol.128, issue.3, 2011.
DOI : 10.1016/j.jaci.2011.04.027

J. Lejeune, G. Thibault, D. Ternant, G. Cartron, H. Watier et al., Evidence for linkage disequilibrium between Fcgamma RIIIa-V158F and Fcgamma RIIa- H131R polymorphisms in white patients, and for an Fcgamma RIIIa-restricted influence on the response to therapeutic antibodies, J Clin Oncol, vol.2619, pp.5489-91, 2008.

G. Raknes, G. Skeie, N. Gilhus, S. Aadland, and C. Vedeler, Fc??RIIA and Fc??RIIIB polymorphisms in myasthenia gravis, Journal of Neuroimmunology, vol.81, issue.1-2, pp.173-179, 1998.
DOI : 10.1016/S0165-5728(97)00174-4

W. Van-der-pol, L. Van-den-berg, R. Scheepers, J. Van-der-bom, P. Van-doorn et al., IgG receptor IIa alleles determine susceptibility and severity of Guillain-Barre syndrome, Neurology, vol.54, issue.8, pp.1661-1666, 2000.
DOI : 10.1212/WNL.54.8.1661

C. Foster, S. Zhu, H. Erichsen, T. Lehrnbecher, E. Hart et al., Polymorphisms in inflammatory cytokines and Fc? receptors in childhood chronic immune thrombocytopenic purpura: a pilot study, Br J Haematol, vol.113, 2001.

S. Bournazos, J. Grinfeld, A. K. Murchison, J. Wallace, W. Mcfarlane et al., Association of Fc??RIIa R131H polymorphism with idiopathic pulmonary fibrosis severity and progression, BMC Pulmonary Medicine, vol.162, issue.2 Pt 1, pp.51-61, 2010.
DOI : 10.1164/ajrccm.162.2.9909053

C. Khor, S. Davila, W. Breunis, Y. Lee, C. Shimizu et al., Genome-wide association study identifies FCGR2A as a susceptibility locus for Kawasaki disease, Nature Genetics, vol.447, issue.12, pp.1241-1247, 2011.
DOI : 10.1038/ng.787

L. Sanders, J. Van-de-winkel, G. Rijkers, M. Voorhorst-ogink, D. Haas et al., Fca Receptor Iia (Cd32) Heterogeneity In Patients With Recurrent Bacterial Respiratory Tract Infections, Journal of Infectious Diseases, vol.170, issue.4, pp.854-61, 1994.
DOI : 10.1093/infdis/170.4.854

A. Duits, H. Bootsma, R. Derksen, P. Spronk, L. Kater et al., Skewed distribution of IGG FC receptor iia (CD32) polymorphism is associated with renal disease in systemic lupus erythematosus patients, Arthritis & Rheumatism, vol.63, issue.12, pp.1832-1838, 1995.
DOI : 10.1002/art.1780381217

J. Edberg, E. Wainstein, J. Wu, E. Csernok, M. Sneller et al., Analysis of FcgammaRII gene polymorphisms in Wegener's granulomatosis, Exp Clin Immunogenet, vol.14, pp.183-95, 1997.

L. Haseley, J. Wisnieski, M. Denburg, A. Michael-grossman, E. Ginzler et al., Antibodies to C1q in systemic lupus erythematosus: Characteristics and relation to Fc??RIIA alleles, Kidney International, vol.52, issue.5, pp.1375-80464, 1997.
DOI : 10.1038/ki.1997.464

Y. Williams, S. Lynch, S. Mccann, O. Smith, C. Feighery et al., Correlation of platelet FcgammaRIIA polymorphism in refractory idiopathic (immune) thrombocytopenic purpura, British Journal of Haematology, vol.10, issue.4, pp.779-82, 1998.
DOI : 10.1016/0167-5699(93)90166-I

K. Myhr, G. Raknes, H. Nyland, and C. Vedeler, Immunoglobulin G Fc-receptor (Fc?R) IIA and IIIB polymorphisms related to disability in MS, Neurology, 1999.

P. Norsworthy, E. Theodoridis, M. Botto, P. Athanassiou, H. Beynon et al., Overrepresentation of the Fc? receptor type IIA R131/R131 genotype in Caucasoid systemic lupus erythematosus patients with autoantibodies to C1q and glomerulonephritis, 9<1828::AID-ANR6>3.0.CO, pp.1828-3210, 1999.

H. Yun, H. Koh, S. Kim, W. Chung, D. Kim et al., Fc??RIIa/IIIa polymorphism and its association with clinical manifestations in Korean lupus patients, Lupus, vol.33, issue.7, pp.466-72, 2001.
DOI : 10.1191/096120301678416015

F. Karassa, T. Trikalinos, and J. Ioannidis, Role of the Fc? receptor IIa polymorphism in susceptibility to systemic lupus erythematosus and lupus nephritis: A meta-analysis, Arthritis & Rheumatism, vol.29, issue.6, pp.1563-71, 2002.
DOI : 10.1002/art.10306

F. Karassa, M. Bijl, K. Davies, C. Kallenberg, M. Khamashta et al., Role of the Fc? receptor IIA polymorphism in the antiphospholipid syndrome: An international meta-analysis, Arthritis & Rheumatism, vol.43, issue.7, pp.1930-1938, 2003.
DOI : 10.1002/art.11059

Y. Tanaka, Y. Suzuki, T. Tsuge, Y. Kanamaru, S. Horikoshi et al., Fc??RIIa-131R allele and Fc??RIIIa-176V/V genotype are risk factors for progression of IgA nephropathy, Nephrology Dialysis Transplantation, vol.20, issue.11, pp.2439-2484, 2005.
DOI : 10.1093/ndt/gfi043

A. Morgan, J. Robinson, J. Barrett, J. Martin, A. Walker et al., Association of FCGR2A and FCGR2A-FCGR3A haplotypes with susceptibility to giant cell arteritis, Arthritis Res Ther, vol.8, pp.10-1186, 2006.

F. Gulen, R. Tanac, S. Altinoz, A. Berdeli, D. Zeyrek et al., The Fc??RIIa polymorphism in Turkish children with asthma bronchial and allergic rhinitis, Clinical Biochemistry, vol.40, issue.5-6, 2007.
DOI : 10.1016/j.clinbiochem.2006.11.014

K. Aksu, G. Kitapcioglu, G. Keser, A. Berdeli, G. Karabulut et al., IIIa and IIIb gene polymorphisms in Behcet's disease: do they have any clinical implications?, Clin Exp Rheumatol, vol.26, pp.77-83, 2008.

J. Woo, Y. Sung, J. Lee, W. Chung, J. Choe et al., Association of Fc?? Receptor Polymorphisms with Adult Onset Still's Disease in Korea, The Journal of Rheumatology, vol.36, pp.347-50, 2009.
DOI : 10.3899/jrheum.071254

C. Kyogoku, H. Dijstelbloem, N. Tsuchiya, Y. Hatta, H. Kato et al., Fc? receptor gene polymorphisms in Japanese patients with systemic

M. Blank, R. Stefanescu, E. Masuda, F. Marti, P. King et al., Decreased transcription of the human FCGR2B gene mediated by the -343 G/C promoter polymorphism and association with systemic lupus erythematosus, Human Genetics, vol.169, issue.2-3, pp.220-227, 2005.
DOI : 10.1007/s00439-005-1302-3

B. Tackenberg, I. Jelcic, A. Baerenwaldt, W. Oertel, N. Sommer et al., Impaired inhibitory Fc?? receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy, Proceedings of the National Academy of Sciences, vol.106, issue.12, pp.4788-92, 2009.
DOI : 10.1073/pnas.0807319106

H. Koene, M. Kleijer, A. Swaak, K. Sullivan, M. Bijl et al., The Fc gammaRIIIA-158F allele is a risk factor for systemic lupus erythematosus, 10<1813::AID-ART13>3.3.CO, pp.1813-1821, 1998.

A. Nieto, R. Cáliz, M. Pascual, L. Matarán, S. García et al., Involvement of Fc?? receptor IIIA genotypes in susceptibility to rheumatoid arthritis, 4<735::AID- ANR3>3.0.CO, pp.735-744, 2000.
DOI : 10.1002/1529-0131(200004)43:4<735::AID-ANR3>3.0.CO;2-Q

J. Edberg, C. Langefeld, J. Wu, K. Moser, K. Kaufman et al., Genetic linkage and association of Fc? receptor IIIA (CD16A) on chromosome 1q23 with human systemic lupus erythematosus, Arthritis & Rheumatism, vol.22, issue.8, pp.2132-2172, 2002.
DOI : 10.1002/art.10438

N. Van-sorge, W. Van-der-pol, M. Jansen, K. Geleijns, S. Kalmijn et al., Severity of Guillain???Barr?? syndrome is associated with Fc?? Receptor III polymorphisms, Journal of Neuroimmunology, vol.162, issue.1-2, pp.157-64, 2005.
DOI : 10.1016/j.jneuroim.2005.01.016

A. Morgan, B. Griffiths, F. Ponchel, B. Montague, M. Ali et al., Fc?? receptor type IIIA is associated with rheumatoid arthritis in two distinct ethnic groups, 10<2328::AID-ANR21>3.0.CO, pp.2328-2362, 2000.
DOI : 10.1002/1529-0131(200010)43:10<2328::AID-ANR21>3.0.CO;2-Z

Y. Lee, J. Ji, and G. Song, Associations Between FCGR3A Polymorphisms and Susceptibility to Rheumatoid Arthritis: A Metaanalysis, The Journal of Rheumatology, vol.35, issue.11, pp.2129-2164, 2008.
DOI : 10.3899/jrheum.080186

I. Bronner, J. Hoogendijk, D. Visser, M. Van-de-vlekkert, J. Badrising et al., Association of the leukocyte immunoglobulin G (Fc??) receptor IIIa-158V/F polymorphism with inflammatory myopathies in Dutch patients, Tissue Antigens, vol.20, issue.6, pp.586-595, 2009.
DOI : 10.1111/j.1399-0039.2009.01236.x

M. Thabet, T. Huizinga, R. Marques, G. Stoeken-rijsbergen, A. Bakker et al., Contribution of Fc?? receptor IIIA gene 158V/F polymorphism and copy number variation to the risk of ACPA-positive rheumatoid arthritis, Annals of the Rheumatic Diseases, vol.68, issue.11, pp.1775-80099309, 2008.
DOI : 10.1136/ard.2008.099309

X. Zhou, J. Lv, D. Bu, Y. L. Yang, Y. Zhao et al., Copy number variation of FCGR3A rather than FCGR3B and FCGR2B is associated with susceptibility to anti-GBM disease, International Immunology, vol.22, issue.1, pp.45-51, 2010.
DOI : 10.1093/intimm/dxp113

Y. Hatta, N. Tsuchiya, J. Ohashi, M. Matsushita, K. Fujiwara et al., Association of Fc?? receptor IIIB, but not of Fc?? receptor IIA and IIIA, polymorphisms with systemic lupus erythematosus in Japanese, Genes and Immunity, vol.1, issue.1, pp.53-60, 1999.
DOI : 10.1038/sj.gene.6363639

W. Tse, S. Abadeh, R. Jefferis, C. Savage, and D. Adu, Neutrophil FcgammaRIIIb allelic polymorphism in anti-neutrophil cytoplasmic antibody (ANCA)-positive systemic vasculitis, Clinical and Experimental Immunology, vol.119, issue.3, 2000.
DOI : 10.1006/cimm.1993.1143

G. Xu, Q. He, Z. Shou, H. Wang, X. Zhang et al., NA1/NA2 heterozygote of Fcgr3b is a risk factor for progression of IgA nephropathy in Chinese, Journal of Clinical Laboratory Analysis, vol.172, issue.5, pp.298-302, 2007.
DOI : 10.1002/jcla.20189

T. Aitman, R. Dong, T. Vyse, P. Norsworthy, M. Johnson et al., Copy number polymorphism in Fcgr3 predisposes to glomerulonephritis in rats and humans, Nature, vol.91, issue.7078, pp.851-856, 2006.
DOI : 10.1002/art.1780251101

M. Fanciulli, P. Norsworthy, E. Petretto, R. Dong, L. Harper et al., FCGR3B copy number variation is associated with susceptibility to systemic, but not organ-specific, autoimmunity, Nature Genetics, vol.86, issue.6, pp.721-724, 2007.
DOI : 10.1126/science.1101160
URL : https://hal.archives-ouvertes.fr/hal-00173649

S. Bournazos, I. Bournazou, J. Murchison, W. Wallace, P. Mcfarlane et al., Copy Number Variation of <i>FCGR3B</i> Is Associated with Susceptibility to Idiopathic Pulmonary Fibrosis, Respiration, vol.81, issue.2, pp.142-151, 2011.
DOI : 10.1159/000321997

S. Graf, S. Lester, J. Nossent, C. Hill, S. Proudman et al., Low copy number of the FCGR3B gene and rheumatoid arthritis: a case-control study and meta-analysis, Arthritis Research & Therapy, vol.14, issue.1, pp.10-1186, 2012.
DOI : 10.1002/art.30141

C. Mckinney, J. Broen, M. Vonk, L. Beretta, R. Hesselstrand et al., Evidence that deletion at FCGR3B is a risk factor for systemic sclerosis, Genes and Immunity, vol.15, issue.6, pp.458-60, 2012.
DOI : 10.1186/ar1847

P. Smith, D. Dilillo, S. Bournazos, F. Li, and J. Ravetch, Mouse model recapitulating human Fc?? receptor structural and functional diversity, Proceedings of the National Academy of Sciences, vol.109, issue.16, pp.6181-6187, 2012.
DOI : 10.1073/pnas.1203954109
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3341029

P. Guyre, R. Graziano, J. Goldstein, P. Wallace, P. Morganelli et al., Increased potency of Fc-receptor-targeted antigens, Cancer Immunology, Immunotherapy, vol.45, issue.3-4, pp.146-154, 1997.
DOI : 10.1007/s002620050418

T. Keler, P. Guyre, L. Vitale, K. Sundarapandiyan, J. Van-de-winkel et al., Targeting Weak Antigens to CD64 Elicits Potent Humoral Responses in Human CD64 Transgenic Mice, The Journal of Immunology, vol.165, issue.12, pp.6738-6780, 2000.
DOI : 10.4049/jimmunol.165.12.6738

I. Heijnen and J. Van-de-winkel, A human Fc gamma RI/CD64 transgenic model for in vivo analysis of (bispecific) antibody therapeutics, J Hematother, vol.4, 1995.

J. Stavenhagen, S. Gorlatov, N. Tuaillon, C. Rankin, H. Li et al., Fc Optimization of Therapeutic Antibodies Enhances Their Ability to Kill Tumor Cells In vitro and Controls Tumor Expansion In vivo via Low-Affinity Activating Fc?? Receptors, Cancer Research, vol.67, issue.18, pp.8882-90, 2007.
DOI : 10.1158/0008-5472.CAN-07-0696

T. Junttila, K. Parsons, C. Olsson, Y. Lu, Y. Xin et al., Superior In vivo Efficacy of Afucosylated Trastuzumab in the Treatment of HER2-Amplified Breast Cancer, Cancer Research, vol.70, issue.11, pp.4481-4490, 2010.
DOI : 10.1158/0008-5472.CAN-09-3704

C. Gerdes, V. Nicolini, S. Herter, E. Van-puijenbroek, S. Lang et al., GA201 (RG7160): A Novel, Humanized, Glycoengineered Anti-EGFR Antibody with Enhanced ADCC and Superior In Vivo Efficacy Compared with Cetuximab, Clinical Cancer Research, vol.19, issue.5, pp.1126-1164, 2013.
DOI : 10.1158/1078-0432.CCR-12-0989

J. Kim and A. Ashkenazi, Fc?? receptors enable anticancer action of proapoptotic and immune-modulatory antibodies, The Journal of Experimental Medicine, vol.127, issue.9, pp.1647-51, 2013.
DOI : 10.1126/science.1160062

J. Mellor, M. Brown, H. Irving, J. Zalcberg, and A. Dobrovic, A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer, Journal of Hematology & Oncology, vol.6, issue.1, pp.1-10, 2013.
DOI : 10.1200/JCO.2009.27.6360

R. Clynes and J. Ravetch, Cytotoxic antibodies trigger inflammation through Fc receptors, Immunity, vol.3, issue.1, pp.21-27, 1995.
DOI : 10.1016/1074-7613(95)90155-8
URL : http://doi.org/10.1016/1074-7613(95)90155-8

S. Mckenzie, S. Taylor, P. Malladi, H. Yuhan, D. Cassel et al., The role of the human Fc receptor Fc gamma RIIA in the immune clearance of platelets: a transgenic mouse model, J Immunol, vol.162, pp.4311-4319, 1999.

S. Taylor, M. Reilly, A. Schreiber, P. Chien, J. Tuckosh et al., Thrombosis and shock induced by activating antiplatelet antibodies in human Fc gamma RIIA transgenic mice: the interplay among antibody, spleen, and Fc receptor, Blood, vol.96, pp.4254-60, 2000.

M. Reilly, S. Taylor, N. Hartman, G. Arepally, B. Sachais et al., Heparin-induced thrombocytopenia/thrombosis in a transgenic mouse model requires human platelet factor 4 and platelet activation through FcgammaRIIA, Blood, vol.98, issue.8, pp.2442-2449, 2001.
DOI : 10.1182/blood.V98.8.2442

L. Rauova, L. Zhai, M. Kowalska, G. Arepally, D. Cines et al., Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: diagnostic and therapeutic implications, Blood, vol.107, issue.6, pp.2346-53, 2006.
DOI : 10.1182/blood-2005-08-3122

T. Meyer, L. Robles-carrillo, T. Robson, F. Langer, H. Desai et al., Bevacizumab immune complexes activate platelets and induce thrombosis in FCGR2A transgenic mice, Journal of Thrombosis and Haemostasis, vol.56, issue.1, pp.171-81, 2009.
DOI : 10.1111/j.1538-7836.2008.03212.x

L. Robles-carrillo, T. Meyer, M. Hatfield, H. Desai, M. Davila et al., Anti-CD40L Immune Complexes Potently Activate Platelets In Vitro and Cause Thrombosis in FCGR2A Transgenic Mice, The Journal of Immunology, vol.185, issue.3, pp.1577-83, 2010.
DOI : 10.4049/jimmunol.0903888

M. Stolla, L. Stefanini, P. Andre, T. Ouellette, M. Reilly et al., CalDAG-GEFI deficiency protects mice in a novel model of Fc??RIIA-mediated thrombosis and thrombocytopenia, Blood, vol.118, issue.4, pp.1113-1133, 2011.
DOI : 10.1182/blood-2011-03-342352

F. Jönsson, D. Mancardi, W. Zhao, Y. Kita, B. Iannascoli et al., Human Fc??RIIA induces anaphylactic and allergic reactions, Blood, vol.119, issue.11, pp.2533-2577, 2012.
DOI : 10.1182/blood-2011-07-367334

S. Petkova, S. Akilesh, T. Sproule, G. Christianson, A. Khabbaz et al., Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease, International Immunology, vol.18, issue.12, pp.1759-69, 2006.
DOI : 10.1093/intimm/dxl110

D. Mancardi, F. Jonsson, B. Iannascoli, H. Khun, N. Van-rooijen et al., Cutting Edge: The Murine High-Affinity IgG Receptor Fc??RIV Is Sufficient for Autoantibody-Induced Arthritis, The Journal of Immunology, vol.186, issue.4, pp.1899-903, 2011.
DOI : 10.4049/jimmunol.1003642

G. Christianson, R. Blankenburg, T. Duffy, D. Panka, and J. Roths, Marshak- Rothstein A, et al. beta2-microglobulin dependence of the lupus-like autoimmune syndrome of MRL-lpr mice, J Immunol, vol.156, pp.4932-4941, 1996.

T. Sardjono, C. Mottram, P. Van-de-velde, N. Powell, M. Power et al., Development of spontaneous multisystem autoimmune disease and hypersensitivity to antibody-induced inflammation in Fc?? receptor IIa-transgenic mice, Arthritis & Rheumatism, vol.13, issue.10, pp.3220-3229, 2005.
DOI : 10.1002/art.21344

N. Van-de-velde, P. Mottram, M. Powell, B. Lim, R. Holmdahl et al., Transgenic mice expressing human FcgammaRIIa have enhanced sensitivity to induced autoimmune arthritis as well as elevated Th17 cells, Immunol Lett, vol.13012, pp.82-90, 2009.

N. Tsuboi, T. Ernandez, X. Li, H. Nishi, X. Cullere et al., Regulation of human neutrophil Fc?? receptor IIa by C5a receptor promotes inflammatory arthritis in mice, Arthritis & Rheumatism, vol.116, issue.2, pp.467-78, 2011.
DOI : 10.1002/art.30141

G. Pietersz, P. Mottram, N. Van-de-velde, C. Sardjono, S. Esparon et al., Inhibition of destructive autoimmune arthritis in Fc??RIIa transgenic mice by small chemical entities, Immunology and Cell Biology, vol.94, issue.1, pp.3-1282, 2008.
DOI : 10.1136/ard.56.6.364

A. Van-vuuren, J. Van-roon, V. Walraven, I. Stuij, M. Harmsen et al., CD64-Directed Immunotoxin Inhibits Arthritis in a Novel CD64 Transgenic Rat Model, The Journal of Immunology, vol.176, issue.10, pp.5833-5841, 2006.
DOI : 10.4049/jimmunol.176.10.5833

T. Thepen, A. Van-vuuren, R. Kiekens, C. Damen, W. Vooijs et al., Resolution of cutaneous inflammation after local elimination of macrophages, Nature Biotechnology, vol.18, issue.1, pp.48-511071908, 1038.
DOI : 10.1038/71908

K. Chen, H. Nishi, R. Travers, N. Tsuboi, K. Martinod et al., Endocytosis of soluble immune complexes leads to their clearance by Fc??RIIIB but induces neutrophil extracellular traps via Fc??RIIA in vivo, Blood, vol.120, issue.22, pp.4421-4452, 2012.
DOI : 10.1182/blood-2011-12-401133

M. Van-vugt, A. Heijnen, P. Capel, S. Park, C. Ra et al., FcR gammachain is essential for both surface expression and function of human Fc gamma RI (CD64) in vivo, Blood, vol.87, pp.3593-3602, 1996.

A. Van-royen-kerkhof, E. Sanders, V. Walraven, M. Voorhorst-ogink, E. Saeland et al., A novel human CD32 mAb blocks experimental immune haemolytic anaemia in FcgammaRIIA transgenic mice, British Journal of Haematology, vol.29, issue.1, 2005.
DOI : 10.1016/0092-8674(94)90115-5

H. Zhi, L. Rauova, V. Hayes, C. Gao, B. Boylan et al., Cooperative integrin/ITAM signaling in platelets enhances thrombus formation in vitro and in vivo, Blood, vol.121, issue.10, pp.1858-67, 2013.
DOI : 10.1182/blood-2012-07-443325

H. Horton, S. Chu, E. Ortiz, E. Pong, S. Cemerski et al., Antibody-Mediated Coengagement of Fc??RIIb and B Cell Receptor Complex Suppresses Humoral Immunity in Systemic Lupus Erythematosus, The Journal of Immunology, vol.186, issue.7, pp.4223-4256, 2011.
DOI : 10.4049/jimmunol.1003412

F. Li and J. Ravetch, Inhibitory Fc?? Receptor Engagement Drives Adjuvant and Anti-Tumor Activities of Agonistic CD40 Antibodies, Science, vol.333, issue.6045, pp.1030-1034, 2011.
DOI : 10.1126/science.1206954

F. Li and J. Ravetch, Antitumor activities of agonistic anti-TNFR antibodies require differential Fc??RIIB coengagement in vivo, Proceedings of the National Academy of Sciences, vol.110, issue.48, pp.19501-19507, 2013.
DOI : 10.1073/pnas.1319502110

M. Li, U. Wirthmueller, and J. Ravetch, Reconstitution of human Fc gamma RIII cell type specificity in transgenic mice, Journal of Experimental Medicine, vol.183, issue.3, pp.1259-63, 1996.
DOI : 10.1084/jem.183.3.1259

D. Roopenian, G. Christianson, T. Sproule, A. Brown, S. Akilesh et al., The MHC Class I-Like IgG Receptor Controls Perinatal IgG Transport, IgG Homeostasis, and Fate of IgG-Fc-Coupled Drugs, The Journal of Immunology, vol.170, issue.7, pp.3528-3561, 2003.
DOI : 10.4049/jimmunol.170.7.3528

A. Mezo, K. Mcdonnell, C. Hehir, S. Low, V. Palombella et al., Reduction of IgG in nonhuman primates by a peptide antagonist of the neonatal Fc receptor FcRn, Proceedings of the National Academy of Sciences, vol.105, issue.7, pp.2337-420708960105, 2008.
DOI : 10.1073/pnas.0708960105